Bø Karl-Erik, Halvorsen Kjell H, Lehnbom Elin C
Department of Pharmacy, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromsø, Norway.
Department of Pharmacy, Uppsala University, Uppsala, Sweden.
Scand J Prim Health Care. 2025 Mar;43(1):241-253. doi: 10.1080/02813432.2024.2439909. Epub 2024 Dec 27.
Multicomponent interventions are increasingly utilized to tackle the complexity of aging and co-morbid patients. However, descriptions of interventions are generally poor, making it difficult for healthcare providers to implement successful programs.
This study aimed to explore the completeness of intervention description of pharmacist-facilitated medication reviews (MRs) in Nordic primary care settings.
We performed a scoping review of studies reporting on pharmacist-facilitated MRs in Nordic primary care settings. Medline, Embase, CINAHL and Web of Science were searched on 24 January 2024. We used Arksey and O'Mally's framework for scoping studies and applied an adapted version of the Template for Intervention Description and Replication (TIDieR) checklist to evaluate intervention reporting. The Pharmaceutical Care Network Europe (PCNE) classification of MR levels was used to identify the components of different MRs.
Sixteen studies were included in this scoping review. The studies were conducted in Sweden ( = 7), Norway ( = 6), Finland ( = 2) and Denmark ( = 1). Information on the participating pharmacists' expertise, qualifications and training was fully reported in only two studies. Twelve studies did not provide any information related to intervention cost, dose or duration, making it challenging to estimate the economic impact of the intervention. Only one study made an evaluation of intervention fidelity. Conversely, 15 studies lacked information on this topic which can lead to inaccurate conclusions about the program's effectiveness.
The studies included in this scoping review do not provide sufficient MR information for intervention replication. We recommend that pharmacy trials use reporting checklists to increase the replicability and transferability of effective interventions.
多组分干预措施越来越多地用于应对老龄化和患有多种疾病患者的复杂性。然而，对干预措施的描述通常很差，这使得医疗保健提供者难以实施成功的项目。
本研究旨在探讨北欧初级保健环境中由药剂师协助进行的药物审查（MRs）的干预描述的完整性。
我们对报告北欧初级保健环境中由药剂师协助进行的MRs的研究进行了范围综述。于2024年1月24日检索了Medline、Embase、CINAHL和科学网。我们使用Arksey和O'Mally的范围研究框架，并应用干预描述与复制模板（TIDieR）清单的改编版本来评估干预报告。采用欧洲药物治疗护理网络（PCNE）的MR水平分类来确定不同MRs的组成部分。
本范围综述纳入了16项研究。这些研究在瑞典（7项）、挪威（6项）、芬兰（2项）和丹麦（1项）进行。只有两项研究充分报告了参与药剂师的专业知识、资格和培训信息。12项研究未提供任何与干预成本、剂量或持续时间相关的信息，这使得估计干预的经济影响具有挑战性。只有一项研究对干预保真度进行了评估。相反，15项研究缺乏关于该主题的信息，这可能导致对项目有效性得出不准确的结论。
本范围综述中纳入的研究没有为干预复制提供足够的MR信息。我们建议药物试验使用报告清单来提高有效干预措施的可复制性和可转移性。
